(11R,15S)-8-ethyl-4-ethylsulfanyl-5-[(4-methoxyphenyl)methyl]-1,3,5,8,10-pentazatetracyclo[7.6.0.02,6.011,15]pentadeca-2(6),3,9-trien-7-one | 682772-26-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: (11R,15S)-8-ethyl-4-ethylsulfanyl-5-[(4-methoxyphenyl)methyl]-1,3,5,8,10-pentazatetracyclo[7.6.0.02,6.011,15]pentadeca-2(6),3,9-trien-7-one
• CAS: 682772-26-5
• 化学式: C₂₂H₂₇N₅O₂S
• 分子量: 425.555
• InChiKey: CEOJGOKUKQPMGH-SJORKVTESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  88.3
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (11R,15S)-8-ethyl-4-ethylsulfanyl-5-[(4-methoxyphenyl)methyl]-1,3,5,8,10-pentazatetracyclo[7.6.0.02,6.011,15]pentadeca-2(6),3,9-trien-7-one 在 sodium perborate 、 溶剂黄146 作用下， 生成 (11R,15S)-8-ethyl-4-ethylsulfonyl-5-[(4-methoxyphenyl)methyl]-1,3,5,8,10-pentazatetracyclo[7.6.0.02,6.011,15]pentadeca-2(6),3,9-trien-7-one
  参考文献：
  名称：

  SAR development of polycyclic guanine derivatives targeted to the discovery of a selective PDE5 inhibitor for treatment of erectile dysfunction

  摘要：

  Development of structure-activity relationship of cyclic guanines I lead us to discovery of a potent and selective series of phosphodiesterase 5 inhibitors 52 59 (IC50 1.3-11.0 nM, PDE6/5 = 116-600). (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.12.027
• 作为产物：
  描述：

  (11R,15S)-8-ethyl-5-[(4-methoxyphenyl)methyl]-1,3,5,8,10-pentazatetracyclo[7.6.0.02,6.011,15]pentadeca-2(6),3,9-trien-7-one 在 lithium diisopropyl amide 作用下， 生成 (11R,15S)-8-ethyl-4-ethylsulfanyl-5-[(4-methoxyphenyl)methyl]-1,3,5,8,10-pentazatetracyclo[7.6.0.02,6.011,15]pentadeca-2(6),3,9-trien-7-one
  参考文献：
  名称：

  SAR development of polycyclic guanine derivatives targeted to the discovery of a selective PDE5 inhibitor for treatment of erectile dysfunction

  摘要：

  Development of structure-activity relationship of cyclic guanines I lead us to discovery of a potent and selective series of phosphodiesterase 5 inhibitors 52 59 (IC50 1.3-11.0 nM, PDE6/5 = 116-600). (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.12.027